Skip to content

Clinical Observation of Regulating Tri-jiao Catgut Embedding Method in the Treatment of Metabolic Associated Fatty Liver Disease.

Clinical Observation of Regulating Tri-jiao Catgut Embedding Method in the Treatment of Metabolic Associated Fatty Liver Disease.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006871
Enrollment
Unknown
Registered
2022-12-19
Start date
2023-01-01
Completion date
Unknown
Last updated
2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Associated Fatty Liver Disease

Interventions

treatment group:catgut embedding

Sponsors

Nanjing Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: (1) Western medicine is in line with the diagnosis of metabolic disorder mafld, traditional Chinese medicine is in line with the syndrome of internal stagnation of dampness and turbidity, which is diagnosed by doctors; (2) Patients aged 18-50 years; (3) No medication or acupuncture catgut embedding related treatment within 3 months; (4) Willing to participate in the experiment of this subject and sign the informed consent form. Note: patients who meet the above four items at the same time can be included in this study.

Exclusion criteria

Exclusion criteria: (1) Mafld caused by endocrine diseases such as thalamic disease, pituitary disease, islet disease and hypothyroidism; (2) History or clinical manifestations of bleeding tendency, including those who are currently using anticoagulants; (3) Those who have received any other treatment within the last 3 months; (4) Patients with obvious liver injury, serum aminotransferase > 2 times the upper limit of normal, and severe liver and kidney dysfunction; (5) Suffering from various serious cardiovascular and cerebrovascular diseases. Note: patients who meet any of the above conditions are excluded.

Design outcomes

Primary

MeasureTime frame
HDL-C;BMI;GGT;FINS;LEP;WC;ADP;LSM;AST;FPG;CAP;TG;LDL-C;BW;TC;ALT;

Countries

China

Contacts

Public ContactRuan Zhizhong
sfy029@niucm.edu.cn13390788707

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026